Skip to main content
OpenTrials
Completed

NCT Number: NCT07179341

Survival Nomogram for Patients With Thymic Carcinoma

Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients.

Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Thymic Carcinoma Hemic and Lymphatic Diseases Lymphatic Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Complex and Mixed Thoracic Neoplasms Thymoma Thymus Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China

Guangzhou, Guangdong, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
  • Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
  • Patients who accepted surgery should be followed up at least six months or reached the endpoint event.

Exclusion criteria

  • The patient had two types of primary tumors concurrently including TC.
  • The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
  • The patient did not obtain a complete pathological report after surgery.

Treatment and study plan

Thymectomy for thymic carcinoma

Procedure

Thymectomy for thymic cancer

Primary outcomes

  1. Overall survival

    Time frame: From date of accepting surgery until the date of final documented or date of death from any cause, whichever came first, assessed up to 325 months

    Overall survival (OS) is the length of time a patient lives after a diagnosis or the start of treatment for a disease, such as cancer

Sponsors and collaborators

Lead sponsor

Weijie Ye

Other

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 17, 2025
Registry last updated
Sep 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.